VIVUS, Inc. (NASDAQ:VVUS) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 535,200 shares, a drop of 7.0% from the September 30th total of 575,500 shares. Based on an average daily volume of 131,900 shares, the days-to-cover ratio is presently 4.1 days. Currently, 5.5% of the shares of the company are sold short.
Shares of VVUS stock opened at $2.86 on Monday. The stock has a market cap of $29.80 million, a P/E ratio of -0.82 and a beta of 1.79. VIVUS has a one year low of $2.15 and a one year high of $5.78. The stock has a fifty day moving average price of $3.65 and a 200 day moving average price of $3.70.
VIVUS (NASDAQ:VVUS) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.30). The company had revenue of $17.97 million during the quarter, compared to analysts’ expectations of $19.13 million. Research analysts anticipate that VIVUS will post -2.94 EPS for the current fiscal year.
A hedge fund recently raised its stake in VIVUS stock. BlackRock Inc. boosted its stake in shares of VIVUS, Inc. (NASDAQ:VVUS) by 6.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,707 shares of the biopharmaceutical company’s stock after acquiring an additional 13,572 shares during the quarter. BlackRock Inc. owned 2.07% of VIVUS worth $843,000 as of its most recent SEC filing. 14.78% of the stock is owned by institutional investors and hedge funds.
VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.